Prognostic value of minimal residual disease monitoring in acute myeloid leukemia patients with t(9;11)(p22;q23).
Tobal
Khalid
K
Department of Hematologic Medicine, King's College Hospital, The Rayne Institute, London, UK. khalid.tobal@kingsch.nhs.uk
D002880:Chromosomes, Human, Pair 11 / Q000235:genetics* / Q000648:ultrastructure; D002899:Chromosomes, Human, Pair 9 / Q000235:genetics* / Q000648:ultrastructure; D006801:Humans; D007951:Leukemia, Myeloid / Q000097:blood / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D051788:Myeloid-Lymphoid Leukemia Protein / Q000097:blood*; D018365:Neoplasm, Residual; D015514:Oncogene Proteins, Fusion / Q000097:blood*; D016133:Polymerase Chain Reaction / Q000379:methods; D011379:Prognosis; D012074:Remission Induction; D016019:Survival Analysis; D014178:Translocation, Genetic; D016896:Treatment Outcome
C474558:MLL-AF9 fusion protein, human; D015514:Oncogene Proteins, Fusion; D051788:Myeloid-Lymphoid Leukemia Protein